Acetylcarnitine
CAS 3040-38-8
Acetylcarnitine (CAS 3040-38-8) is a Phase 3 pharmaceutical compound with 2 bioactivity targets and 12 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 29507.19323943662 nM | 71 | - |
| - | Potency | 37857.333333333336 nM | 3 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| acetylcarnitine | 193 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Acetylcarnitine used for in pharmaceutical contexts?
Acetylcarnitine (CAS 3040-38-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Acetylcarnitine?
Acetylcarnitine has 12 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Drug ineffective, Muscle spasms, Muscle twitching, Paraesthesia, Dysphagia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Acetylcarnitine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Acetyl L-Carnitine with EU status "permitted".
What clinical phase is Acetylcarnitine in?
Acetylcarnitine is rendered with ChEMBL max phase 3.